TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7694148
Drug: s-BACOP (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: s-BACOP (standard doses of doxorubicin)
Study: 27448264
Drug: Brief Systemic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Systemic Therapy (BST)
Study: 12780836
Drug: Neodymium: YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neodymium: YAG laser therapy
Study: 10850578
Drug: Recombinant activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant activated factor VII (rFVIIa; NovoSeven) as a single intravenous bolus dose
Study: 15321288
Drug: Meptazinol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meptazinol (10 mg PCA bolus)
Study: 15321288
Drug: Morphine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (1 mg PCA bolus)
Study: 8238798
Drug: loratadine 10
Normalized name: loratadine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: loratadine 10 mg daily for 2 weeks
Study: 8238798
Drug: terfenadine 60
Normalized name: terfenadine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine 60 mg twice daily for 2 weeks
Study: 31010031
Drug: Specific collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific collagen peptides (SCP) 15 g daily
Study: 23625328
Drug: Nintedanib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib 200 mg twice daily
Study: 19548488
Drug: Chlorine dioxide
Normalized name: Chlorine dioxide
DrugBank: Chlorine dioxide (DB12453)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorine dioxide waterline cleaner treatment
Study: 17806055
Drug: Micafungin 150
Normalized name: micafungin 150 MG in 150 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin 150 mg daily
Study: 17806055
Drug: Caspofungin (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caspofungin (70 mg followed by 50 mg daily)
Study: 15471825
Drug: Carvedilol, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol, 50 mg/d
Study: 15471825
Drug: Metoprolol, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol, 100 mg/d
Study: 11058707
Drug: Omacor (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omacor (4 g/day)
Study: 8874910
Drug: Cisatracurium (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium (0.1 mg. kg‐1)
Study: 8874910
Drug: Atracurium (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atracurium (0.5 mg. kg‐1)
Study: 8874910
Drug: Cisatracurium (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium (0.15 mg. kg‐1)
Study: 8874910
Drug: Cisatracurium (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium (0.2 mg. kg‐1)
Study: 8874910
Drug: Cisatracurium (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium (2 x ED95 doses)
Study: 8874910
Drug: Cisatracurium (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium (3 x ED95 doses)
Study: 8874910
Drug: Cisatracurium (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisatracurium (4 x ED95 doses)
Study: 1328143
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparins (LMW-heparins) administered subcutaneously
Study: 1328143
Drug: Classical intravenous
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Classical intravenous heparin therapy
Study: 27760933
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy using FP(CF) plus docetaxel
Study: 27760933
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy using FP(CF) plus radiation (FP(CF)-RT)
Study: 27760933
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy using FP(CF)
Study: 27760933
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy using DCF
Study: 27760933
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy using FP(CF)-RT
Study: 20585755
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation treatment (10 treatments vaginally and transanally over 5-7 weeks)
Study: 20585755
Drug: Tolterodine 4
Normalized name: tolterodine 4 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 4 mg orally once daily
Study: 18180882
Drug: Milk-powder-based dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk-powder-based dietary supplement providing 50 mg Ca, 250 mg Ca, or 500 mg Ca, or 500 mg Ca plus multivitamins, iron, and zinc, given daily, 6 days/week for 13 months.
Study: 18180882
Drug: Milk-powder-based dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk-powder-based dietary supplement providing 50 mg Ca (lowest amount).
Study: 16868704
Drug: Standard calcium
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard calcium and magnesium dialysis solution (SCa-MgD) (Ca: 1.62 mmol/l, Mg: 0.75 mmol/l)
Study: 16868704
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium and magnesium dialysis solution (LCa-MgD) (Ca: 1.25 mmol/l, Mg: 0.25 mmol/l)
Study: 12786634
Drug: Pantoprazole, 20
Normalized name: Pantoprazole, 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole, 20 mg daily for 6 months
Study: 8805033
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone treatment in short normal children
Study: 8805033
Drug: Chemotherapy in
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy in children with acute lymphoblastic leukaemia
Study: 8805033
Drug: High-dose dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dexamethasone in babies with bronchopulmonary dysplasia
Study: 1535301
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg intravenous methylprednisolone at 8 AM
Study: 1535301
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg intravenous methylprednisolone at 4 PM
Study: 1535301
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug administration
Study: 27614145
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of midodrine and tolvaptan
Study: 23370049
Drug: Yo-Yo intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yo-Yo intermittent recovery test level 1 (Yo-Yo IR1) training, 6-week program, twice a week
Study: 17587516
Drug: isopropanolic extract
Normalized name: isopropanol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: isopropanolic extract of Actaea racemosa (iCR, Remifemin) 40 mg crude drug/day
Study: 12015521
Drug: Oral estrogen/medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogen/medroxyprogesterone acetate (HRT)
Study: 12015521
Drug: Oral estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estrogen (ERT)
Study: 341947
Drug: Single night-time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single night-time dose of mianserin 60 mg
Study: 341947
Drug: Three times
Normalized name: WELLBUTRIN 100 MG Oral Tablet, Three Times Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times daily regimen of mianserin
Study: 31774552
Drug: Sublingual nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual nifedipine (20 mg loading dose, repeated every 30 minutes, maximum dose of 60 mg)
Study: 31774552
Drug: Oral nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine (20 mg loading dose, repeated every 30 minutes, maximum dose of 60 mg)
Study: 26237520
Drug: High-dose cholecalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cholecalciferol (daily 50,000 IU vitamin D3)
Study: 26237520
Drug: Low-dose cholecalciferol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cholecalciferol (daily 800 IU vitamin D3)
Study: 26237520
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily white and twice monthly yellow placebo)
Study: 16436824
Drug: Bone scintigraphy
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone scintigraphy with SPECT prior to injection (Group A1)
Study: 16436824
Drug: Facet joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facet joint injections at levels indicated by referring physician without bone scintigraphy (Group B)
Study: 16436824
Drug: Facet joint
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facet joint injections at levels decided as in group B (Group A2)
Study: 15327411
Drug: Adefovir dipivoxil
Normalized name: Adefovir Dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Adefovir dipivoxil (ADV) 30 mg daily
Study: 9315530
Drug: Tirofiban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban (10 microg/kg bolus over 3 minutes followed by 0.15 microg x kg(‐1) x min(‐1) infusion for 36 hours)
Study: 3574819
Drug: Single preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative dose of cefazolin
Study: 3574819
Drug: Three perioperative
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three perioperative doses of cefazolin
Study: 3574819
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of cefonicid
Study: 27279544
Drug: Cabozantinib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (60 mg once a day)
Study: 23567376
Drug: In-person problem-solving
Normalized name: Psoriasin Problem Skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-person problem-solving therapy (PST)
Study: 23226893
Drug: Psycho-education, case
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psycho-education, case management, interpersonal psychotherapy and/or antidepressants by lay health workers
Study: 23226893
Drug: Physician treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician treatment
Study: 7547090
Drug: Tenidap sodium
Normalized name: tenidap sodium
DrugBank: Tenidap (DB13481)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenidap sodium (120 mg)
Study: 2286595
Drug: Amoxycillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanic acid 500/125 mg three times daily
Study: 7042361
Drug: Indoprofen, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indoprofen, 600 mg daily
Study: 7042361
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA), 3 g daily
Study: 29794828
Drug: Bictegravir, emtricitabine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bictegravir, emtricitabine, and tenofovir alafenamide (after switching from initial treatment)
Study: 29794828
Drug: Bictegravir or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bictegravir or dolutegravir with emtricitabine and tenofovir alafenamide (initial treatment)
Study: 27249205
Drug: Crushed eslicarbazepine
Normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed eslicarbazepine acetate (800 mg)
Study: 27249205
Drug: Intact eslicarbazepine
Normalized name: Eslicarbazepine
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact eslicarbazepine acetate (800 mg)
Study: 23300624
Drug: 10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg iloprost
Study: 23300624
Drug: 20 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 µg iloprost
Study: 18547173
Drug: Injection techniques
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection techniques that increase the dissection of the subepidermal plane (e.g., fanlike needle use, rapid injection, rapid flow rates, and higher volumes)
Study: 18547173
Drug: Injection techniques
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection techniques that increase epidermal damage or subcutaneous exposure (e.g., multiple punctures or deep subcutaneous injection)
Study: 18547173
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection correction, depth of injection, and NASHA product injected
Study: 16080579
Drug: IL-2, 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2, 1.8 x 10(6) I.U. for 5 days/week for 2 consecutive cycles of 3 weeks, with a 1-week interval plus oral RA, 0.5 mg/Kg (arm B)
Study: 10559528
Drug: 100 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/kg oral methionine
Study: 8885917
Drug: Corticosteroids after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids after treatment with ampicillin-sulbactam
Study: 30916121
Drug: 12.5% maltodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5% maltodextrin (200 mL, 2 h before anesthesia)
Study: 30916121
Drug: Intraoperative infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative infusion of ω‐3 PUFA (0.2 g/kg)
Study: 30916121
Drug: Water (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (200 mL, 2 h before anesthesia) plus intraoperative infusion of ω‐3 PUFA (0.2 g/kg)
Study: 30916121
Drug: Intraoperative infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative infusion of ω‐3 PUFA
Study: 27032700
Drug: Sequential FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential FOLFIRI followed by docetaxel/cisplatin
Study: 27032700
Drug: 5-fluorouracil monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-fluorouracil monotherapy
Study: 22289414
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of brain-teasers and dynamic imagery tasks
Study: 20336040
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bacterial wound colonization and procalcitonin blood level > or =2 ng/ml
Study: 18476417
Drug: Qishen Huoxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qishen Huoxue Granule (QHG) plus conventional Western medicine
Study: 1684750
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg (SOD)
Study: 1684750
Drug: Hydroxyzine 20
Normalized name: pentaerythritol/hydroxyzine 20 mg-10 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 20 mg (SOD)
Study: 6580840
Drug: Vindesine (VDS;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vindesine (VDS; 2 mg/m2 i.v., twice or once weekly) in combination with prednisolone (Pred; 40 mg/m2 p.o., daily)
Study: 6580840
Drug: Vincristine (VCR;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine (VCR; 1.2 mg/m2 i.v., once weekly) in combination with prednisolone (Pred; 40 mg/m2 p.o., daily)
Study: 31869400
Drug: Trastuzumab administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab administration
Study: 31004075
Drug: galcanezumab 150
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: galcanezumab 150 mg biweekly for 12 weeks
Study: 26896964
Drug: Specific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific treatment arm rather than randomization
Study: 22219517
Drug: Resveratrol (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (1, 1.5, or 2 g daily for 4 weeks)
Study: 19794285
Drug: Clodronate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (100 mg every week) plus Calcium (500 mg daily) and Vitamin D3 (800 mg daily)
Study: 19794285
Drug: Supplements only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplements only (Calcium 500 mg daily and Vitamin D3 800 mg daily)
Study: 17932438
Drug: MTCT prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTCT prophylaxis (3 short course zidovudine (AZT), 19 single-dose nevirapine (NVP), 5 both AZT and NVP)
Study: 17932438
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose NVP for infants
Study: 8156864
Drug: Trial Coordinator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial Coordinator activities including recruitment, screening, medical management, education and training, adherence and administration
Study: 28132762
Drug: Previously published
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previously published equations (e.g., Slaughter).
Study: 19894388
Drug: XIAs No.
Approvals — FDA: no, EMA: no, PMDA: no
Description: XIAs No. 1 Sleeping Prescription
Study: 19894388
Drug: Estazolam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estazolam (1 mg) for 6 weeks
Study: 17129304
Drug: Subhepatic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subhepatic administration of 20 mL of 0.5% bupivacaine just after the creation of pneumoperitoneum (group 2)
Study: 17129304
Drug: Subhepatic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subhepatic administration of 20 mL of 0.5% bupivacaine before pneumoperitoneum (group 1)
Study: 17129304
Drug: Subhepatic administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subhepatic administration of 20 mL of 0.5% bupivacaine just before removal of the trocars (group 3)
Study: 11453891
Drug: Flomoxef (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flomoxef (1 g) at 09.00 h
Study: 11453891
Drug: Flomoxef (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flomoxef (1 g) at 21.00 h
Study: 2647666
Drug: Flunarizine 20
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine 20 mg i.v.
Study: 29018067
Drug: Midwives administering
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midwives administering 600 µg misoprostol orally
Study: 29018067
Drug: Physicians administering
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physicians administering 600 µg misoprostol orally
Study: 23873553
Drug: Thymol +
Normalized name: Thymol
DrugBank: Thymol (DB02513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thymol + carvacrol at 200 mg/kg diet
Study: 15753151
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 IU/day, 1 month) + Vitamin C (1000 g/day)
Study: 9064059
Drug: Daflon 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daflon 500 mg (2 tabs/day)
Study: 7761669
Drug: Evening i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening i.v. administration of erythropoietin (rHuEPO)
Study: 7761669
Drug: Morning i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning i.v. administration of erythropoietin (rHuEPO)
Study: 27545119
Drug: SAR252067 (40,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR252067 (40, 120, 300, 600, 900, or 1200 mg)
Study: 27545119
Drug: SAR252067 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR252067 (40 mg)
Study: 25691681
Drug: Sucroferric oxyhydroxide
Normalized name: Sucroferric Oxyhydroxide
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucroferric oxyhydroxide 1.0-3.0 g/day (4.0 ± 1.5 tablets/day)
Study: 25691681
Drug: Sevelamer 2.4-14.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevelamer 2.4-14.4 g/day (10.1 ± 6.6 tablets/day)
Study: 18460643
Drug: Denosumab (escalating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (escalating doses)
Study: 14507293
Drug: Group W1
Normalized name: Neisseria meningitidis serogroup W135 conjugated Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group W1 (65% VO2max, 300 kcal in one daily walking bout)
Study: 14507293
Drug: Group W2
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group W2 (65% VO2max, 300 kcal in two daily walking bouts)
Study: 11115683
Drug: Cochlear implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear implant use
Study: 31618698
Drug: Decongestive therapies
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decongestive therapies
Study: 26501831
Drug: Systemic magnesium
Normalized name: Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic magnesium infusion (initial loading dose 30 mg/kg over 15 minutes followed by continuous infusion 10 mg/kg/h)
Study: 26501831
Drug: Systemic magnesium
Normalized name: Vaginal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic magnesium infusion
Study: 24171961
Drug: Improved PAD
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved PAD (subcutaneous injection of bortezomib)
Study: 24171961
Drug: PAD (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAD (conventional treatment)
Study: 20508979
Drug: Immediate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate treatment (IT)
Study: 18309943
Drug: Trimodality therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimodality therapy (cisplatin 100 mg/m² and fluorouracil 1,000 mg/m²/d for 4 days on weeks 1 and 5 concurrent with radiation therapy 50.4 Gy total: 1.8 Gy/fraction over 5.6 weeks) followed by esophagectomy with node dissection
Study: 12702891
Drug: Mirtazapine 30‐45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine 30‐45 mg/day
Study: 12702891
Drug: Paroxetine 20‐30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20‐30 mg/day
Study: 12848626
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate (15-25 mg)
Study: 12848626
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate with 5 mg folic acid (15-25 mg)